SanBio Company Limited
SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system. It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. The company's research pipeline products also comprise SB623 for chronic cerebral infarction and chronic traumatic cerebral infarction inj… Read more
SanBio Company Limited (SNBIF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of January 2022: -0.755x
Based on the latest financial reports, SanBio Company Limited (SNBIF) has a cash flow conversion efficiency ratio of -0.755x as of January 2022.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.54 Billion) by net assets ($2.04 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
SanBio Company Limited - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how SanBio Company Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
SanBio Company Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SanBio Company Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Polynovo Ltd
AU:PNV
|
0.190x |
|
Daqian Ecology & Landscape Co Ltd
SHG:603955
|
-0.030x |
|
Eastern Communications Co Ltd B
SHG:900941
|
0.033x |
|
RWS Holdings plc
PINK:RWSPF
|
0.044x |
|
Chengdu Xiling Power Science & Technology Incorporated Co Class A
SHE:300733
|
0.070x |
|
Tremor International Ltd
PINK:TTTPF
|
0.098x |
|
Intrum AB (publ)
PINK:ITJTY
|
0.155x |
|
Eurocrane China Co Ltd
SHG:603966
|
0.072x |
Annual Cash Flow Conversion Efficiency for SanBio Company Limited (2014–2025)
The table below shows the annual cash flow conversion efficiency of SanBio Company Limited from 2014 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-01-31 | $1.76 Billion | $-3.60 Billion | -2.044x | -19.76% |
| 2024-01-31 | $2.79 Billion | $-4.77 Billion | -1.707x | -1.67% |
| 2023-01-31 | $4.43 Billion | $-7.43 Billion | -1.679x | +47.81% |
| 2022-01-31 | $2.04 Billion | $-6.55 Billion | -3.216x | -415.00% |
| 2021-01-31 | $8.35 Billion | $-5.21 Billion | -0.625x | -19.41% |
| 2020-01-31 | $10.93 Billion | $-5.72 Billion | -0.523x | -17.44% |
| 2019-01-31 | $8.91 Billion | $-3.97 Billion | -0.445x | +80.11% |
| 2018-01-31 | $851.00 Million | $-1.91 Billion | -2.240x | -473.02% |
| 2017-01-31 | $4.59 Billion | $-1.80 Billion | -0.391x | -82.66% |
| 2016-01-31 | $6.37 Billion | $-1.36 Billion | -0.214x | -108.64% |
| 2015-01-31 | $-88.00 Million | $-218.00 Million | 2.477x | +2130.68% |
| 2014-01-31 | $-1.96 Billion | $-218.00 Million | 0.111x | -- |